31 results on '"Schouten, Harry C."'
Search Results
2. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands
- Author
-
van den Beuken-van Everdingen, Marieke H.J., de Rijke, Janneke M., Kessels, Alfons G., Schouten, Harry C., van Kleef, Maarten, and Patijn, Jacob
- Published
- 2007
- Full Text
- View/download PDF
3. Quality of life after stem cell transplantation: a patient, partner and physician perspective
- Author
-
Hendriks, Mariëlle G.J and Schouten, Harry C
- Published
- 2002
- Full Text
- View/download PDF
4. Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature.
- Author
-
Slot, Stefanie, Raymakers, Reinier A.P., Schaap, Nicolaas, Span, Lambert F.R., Koene, Harry R., Kersting, Sabina, te Boekhorst, Peter A.W., Westerman, Matthijs, Schouten, Harry C., and Zweegman, Sonja
- Published
- 2019
- Full Text
- View/download PDF
5. Murine dendritic cells that are resistant to maturation are unable to induce tolerance to allogeneic stem cells.
- Author
-
Vanclée, Ariane, Schouten, Harry C., and Bos, Gerard M. J.
- Subjects
- *
DENDRITIC cells , *STEM cells , *ANTIGEN presenting cells , *LYMPHOID tissue , *CELL growth , *ANTIGENS - Abstract
Induction of donor-specific hyporesponsiveness would minimize the need for intensive immunosuppression in the clinical setting of graft rejection and dendritic cells (DCs) might be useful tools for this purpose. Besides their ability to induce immunogenic T-cell responses, these antigen presenting cells can lead to T-cell anergy, when antigen presentation occurs in the absence of costimulation as is the case in immature DCs (iDCs). In continuance of publications reporting on the use of iDCs to induce tolerance to various organs, we set out to determine whether tolerance could be induced in a model of allogeneic stem cell transplantation. Immature DCs were obtained by culture with very low concentrations of GMCSF and by treating DCs with Dexamethasone (Dex). We show that these DCs express low levels of MHCII and costimulatory molecules and that this immature phenotype is retained after application of maturation stimuli. We also prove that these alternatively activated DCs are unable to induce T-cell proliferation in vitro. When used in vivo however, these tolerogenic DCs do not provide tolerance to fully mismatched or haploidentical stem cells. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
6. forewordglossary of frequently used abbreviated hematological terms.
- Author
-
Schouten, Harry C.
- Subjects
- *
PREFACES & forewords , *ONCOLOGY - Abstract
A foreword to the journal "Annals of Oncology" which focuses on hematological malignancies and a glossary of commonly-abbreviated hematological terms is presented.
- Published
- 2007
- Full Text
- View/download PDF
7. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
- Author
-
DeFilipp, Zachariah, Ancheta, Richard, Liu, Ying, Hu, Zhen-Huan, Gale, Robert Peter, Snyder, David, Schouten, Harry C., Kalaycio, Matt, Hildebrandt, Gerhard C., Ustun, Celalettin, Daly, Andrew, Ganguly, Siddhartha, Inamoto, Yoshihiro, Litzow, Mark, Szer, Jeffrey, Savoie, Mary Lynn, Hossain, Nasheed, Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, and Reshef, Ran
- Subjects
- *
CHRONIC myeloid leukemia , *HEMATOPOIETIC stem cell transplantation , *PROTEIN-tyrosine kinases , *KINASE inhibitors , *BONE marrow , *ALEMTUZUMAB - Abstract
• Maintenance tyrosine kinase inhibitor (TKI) therapy did not significantly impact outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) performed to treat chronic myelogenous leukemia. • Results were not modified by the status of disease before transplantation. • The optimal approach to TKI therapy after allo-HCT remains undetermined. It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML who underwent transplantation between 2007 and 2014 and received maintenance TKI following HCT (n = 89) compared with no TKI maintenance (n = 301), as reported to the Center for International Blood and Marrow Transplant Research. All patients received TKI therapy before HCT. The majority of patients had a disease status of first chronic phase at HCT (n = 240; 62%). The study was conducted as a landmark analysis, excluding patients who died, relapsed, had chronic graft-versus-host disease, or were censored before day +100 following HCT. Of the 89 patients who received TKI maintenance, 77 (87%) received a single TKI and the other 12 (13%) received multiple sequential TKIs. The most common TKIs used for maintenance were dasatinib (n = 50), imatinib (n = 27), and nilotinib (n = 27). As measured from day +100, the adjusted estimates for 5-year relapse (maintenance, 35% versus no maintenance, 26%; P =.11), leukemia-free survival (maintenance, 42% versus no maintenance, 44%; P =.65), or overall survival (maintenance, 61% versus no maintenance, 57%; P =.61) did not differ significantly between patients receiving TKI maintenance or no maintenance. These results remained unchanged in multivariate analysis and were not modified by disease status before transplantation. In conclusion, our data from this day +100 landmark analysis do not demonstrate a significant impact of maintenance TKI therapy on clinical outcomes. The optimal approach to TKI administration in the post-transplantation setting in patients with CML remains undetermined. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
- Author
-
Bromberg, Jacoline E C, Issa, Samar, Bakunina, Katerina, Minnema, Monique C, Seute, Tatjana, Durian, Marc, Cull, Gavin, Schouten, Harry C, Stevens, Wendy B C, Zijlstra, Josee M, Baars, Joke W, Nijland, Marcel, Mason, Kylie D, Beeker, Aart, van den Bent, Martin J, Beijert, Max, Gonzales, Michael, de Jong, Daphne, and Doorduijn, Jeanette K
- Subjects
- *
RITUXIMAB , *DIFFUSE large B-cell lymphomas , *CLINICAL trial registries , *CYTARABINE , *BLOOD-brain barrier , *LYMPHOMAS , *CELL membranes - Abstract
Background: The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low penetration of the large rituximab molecule through the blood-brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma.Methods: This intergroup, multicentre, open-label, randomised phase 3 study was done at 23 hospitals in the Netherlands, Australia, and New Zealand. Non-immunocompromised patients aged 18-70 years with newly diagnosed primary CNS lymphoma were randomly assigned (1:1) to receive methotrexate-based chemotherapy with or without intravenous rituximab. We used a web-based randomisation system with stratification by centre, age, and Eastern Cooperative Oncology Group-WHO performance status, and a minimisation procedure. All group assignment was open label and neither investigators nor patients were masked to allocation. All patients were treated with two 28-day cycles of induction chemotherapy, consisting of intravenous methotrexate 3 g per m2 on days 1 and 15, intravenous carmustine 100 mg per m2 on day 4, intravenous teniposide 100 mg per m2 on days 2 and 3, and oral prednisone 60 mg per m2 on days 1-5, with (R-MBVP) or without (MBVP) intravenous rituximab 375 mg per m2 on days 0, 7, 14, and 21 in cycle one and days 0 and 14 in cycle two. Patients with response at the end of induction subsequently received high-dose cytarabine and, in patients aged 60 years or younger, low-dose whole-brain radiotherapy. The primary endpoint was event-free survival, with events defined as not reaching complete response or complete response unconfirmed at the end of treatment, or progression or death after response; analysis was adjusted for age and performance score. Patients were analysed on a modified intention-to-treat basis. This trial is registered with the Nederlands Trial Register, number NTR2427, and the Australian New Zealand Clinical Trials Registry, number ACTRN12610000908033. The trial was closed on May 27, 2016, after achieving complete accrual, and follow-up is ongoing.Findings: Between Aug 3, 2010, and May 27, 2016, we recruited 200 patients (109 men and 91 women; median age was 61 years [IQR 55-67]). We randomly assigned 100 patients to MBVP and 99 patients to R-MBVP. One patient was randomly assigned to the R-MBVP group but found to be ineligible because of an incorrect diagnosis and was excluded from all analyses. After a median follow-up of 32·9 months (IQR 23·9-51·5), 98 patients had had an event (51 in the MBVP group and 47 in the R-MBVP group), of whom 79 had died (41 in the MBVP group and 38 in the R-MBVP group). Event-free survival at 1 year was 49% (95% CI 39-58) in the MBVP group (no rituximab) and 52% (42-61) in the R-MBVP group (with rituximab; hazard ratio 1·00, 95% CI 0·70-1·43, p=0·99). Grade 3 or 4 adverse events occurred in 58 (58%) patients in the MBVP group and 63 (64%) patients in the R-MBVP group, with infections (24 [24%] patients receiving MBVP vs 21 [21%] patients receiving R-MBVP), haematological toxicity (15 [15%] vs 12 [12%]), and nervous system disorders (ten [10%] vs 15 [15%]) being the most common. Life-threatening or fatal serious adverse events occurred in 12 (12%) patients in the MBVP group and ten (10%) patients in the R-MBVP group, and five (5%) patients in the MBVP group and three (3%) in the R-MBVP group died from treatment-related causes.Interpretation: We found no clear benefit of addition of rituximab to methotrexate, carmustine, teniposide, and prednisone chemotherapy in primary CNS lymphoma. Therefore, the results of this study do not support the use of rituximab as a component of standard treatment in primary CNS lymphoma.Funding: Roche, the Dutch Cancer Society, and Stichting STOPhersentumoren. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
- Author
-
Chhabra, Saurabh, Liu, Ying, Hemmer, Michael T., Costa, Luciano, Pidala, Joseph A., Couriel, Daniel R., Alousi, Amin M., Majhail, Navneet S., Stuart, Robert K., Kim, Dennis, Ringden, Olle, Urbano-Ispizua, Alvaro, Saad, Ayman, Savani, Bipin N., Cooper, Brenda, Marks, David I., Socie, Gerard, Schouten, Harry C., Schoemans, Helene, and Abdel-Azim, Hisham
- Subjects
- *
CALCINEURIN , *METHOTREXATE , *MYCOPHENOLIC acid , *GRAFT versus host disease , *TACROLIMUS - Abstract
Highlights • There is lack of comparative efficacy analysis between mycophenolate-calcineurin inhibitor (CNI) and methotrexate-CNI regimens for graft-versus-host disease (GVHD) prophylaxis in the setting of reduced-intensity conditioning (RIC) allogeneic transplantation. • In this retrospective cohort study evaluating the efficacy of the 4 commonly used CNI-based regimens in a large cohort of patients, the mycophenolate-based approach showed a higher risk for acute GVHD and nonrelapse mortality in RIC allogeneic transplant recipients with unrelated donor. Nonetheless, lack of overall survival advantage suggests that no GVHD prophylaxis regimen is superior. ABSTRACT The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P <.001) and grade III to IV acute GVHD (RR, 1.93; P =.006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P =.008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry.
- Author
-
Martino, Massimo, Lanza, Francesco, Pavesi, Lorenzo, Öztürk, Mustafa, Blaise, Didier, Leno Núñez, Rubén, Schouten, Harry C., Bosi, Alberto, De Giorgi, Ugo, Generali, Daniele, Rosti, Giovanni, Necchi, Andrea, Ravelli, Andrea, Bengala, Carmelo, Badoglio, Manuela, Pedrazzoli, Paolo, and Bregni, Marco
- Subjects
- *
CANCER chemotherapy , *HEMATOPOIETIC stem cell transplantation , *IMMUNOLOGICAL adjuvants , *DRUG therapy , *BREAST cancer research , *MEDICAL registries - Abstract
The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had ≥10 positive lymph nodes at surgery. Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at .9% between 2001 and 2005, whereas secondary tumor-related mortality was .9%. With a median follow-up of 120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole population were 75% and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were significantly better in patients with endocrine-responsive tumors, <10 positive lymph nodes, and smaller tumor size. HER2 status did not affect survival probability. Adjuvant HDC with AHSCT has a low mortality rate and provides impressive long-term survival rates in patients with high-risk BC. Our results suggest that this treatment modality should be considered in selected high-risk BC patients and further investigated in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. OR40 Site of HLA-B/C recombination identified by STR analysis and sequencing.
- Author
-
Voorter, Chrisitina E.M., Groeneweg, Mathijs, Schouten, Harry C., Groeneveld, Lisette, and Tilanus, Marcel G.J.
- Subjects
- *
NUCLEOTIDE sequencing , *STEM cell transplantation , *HLA histocompatibility antigens , *IMMUNOGLOBULINS , *MEDICAL screening - Abstract
Recombination events have been reported between HLA-A/C, HLA-B/DRB1 and HLA-DQB1/DPB1. To our knowledge no proven recombination event between HLA-B and -C has ever been found. In a sibling of a stem cell transplant candidate, the candidate and 3 siblings were typed and a pedigree with 4 different haplotypes could be established, but with very rare B-C segregation patterns (B*35∼C*05, B*44∼C*04). We performed STR analysis (Identifiler, ABI) to confirm sib relationship amongst the 4 individuals. If common HLA-B ∼C associations (B*35∼C*04, B*44∼C*05) were considered, 3 haplotypes could be identified and segregation patterns revealed one common haplotype for all individuals and the occurrence of a C/B recombination in one of the individuals. To investigate this possibility STR analysis was performed with informative markers D6S2838, D6S2851 (telomeric of HLA-A), D6S510, D6S265, D6S2931 (between HLA-A and -C), D6S2811, D6S2928 (between HLA-C and -B), MIB, D6S2792, D6S2787, D6S2920, D6S2894, D6S2883 (between HLA-B and -DRB1), D6S1666 and G51152 (centromeric of HLA-DQB1). The individual with the possible recombination event showed STR markers identical to one sibling with the same HLA-A and -C typing up to marker D6S2928, whereas the markers between HLA-B and -DRB1 and telomeric of DQB1 were identical to the other two siblings with identical HLA-B, -DRB1 and -DQB1 typing results. The region of the recombination was further narrowed by sequencing the area between HLA-B and D6S2928. This showed the recombination event to have taken place in the highly conserved sequence between 847 and 1228 bases after the HLA-B STOP codon. In conclusion, this is the first report confirming a recombination event between HLA-B and -C identified in a family of a stem cell transplant candidate. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation.
- Author
-
Copelan, Edward A., Avalos, Belinda R., Ahn, Kwang Woo, Zhu, Xiaochun, Gale, Robert Peter, Grunwald, Michael R., Hamadani, Mehdi, Hamilton, Betty K., Hale, Gregory A., Marks, David I., Waller, Edmund K., Savani, Bipin N., Costa, Luciano J., Ramanathan, Muthalagu, Cahn, Jean-Yves, Khoury, H. Jean, Weisdorf, Daniel J., Inamoto, Yoshihiro, Kamble, Rammurti T., and Schouten, Harry C.
- Subjects
- *
MYELOID leukemia , *LEUKEMIA treatment , *GRAFT versus host disease , *HEALTH outcome assessment , *CYCLOPHOSPHAMIDE , *INTRAVENOUS therapy , *COMPARATIVE studies , *BUSULFAN , *TOTAL body irradiation - Abstract
Cyclophosphamide (Cy) in combination with busulfan (Bu) or total body irradiation (TBI) is the most commonly used myeloablative conditioning regimen in patients with chronic myeloid leukemia (CML). We used data from the Center for International Bone Marrow Transplantation Research to compare outcomes in adults who underwent hematopoietic cell transplantation for CML in first chronic phase after myeloablative conditioning with Cy in combination with TBI, oral Bu, or intravenous (i.v.) Bu. Four hundred thirty-eight adults received human leukocyte antigen (HLA)-matched sibling grafts and 235 received well-matched grafts from unrelated donors (URD) from 2000 through 2006. Important differences existed between the groups in distribution of donor relation, exposure to tyrosine kinase inhibitors, and year of transplantation. In multivariate analysis, relapse occurred less frequently among patients receiving i.v. Bu compared with TBI (relative risk [RR], .36; P = .022) or oral Bu (RR, .39; P = .028), but nonrelapse mortality and survival were similar. A significant interaction was detected between donor relation and the main effect in leukemia-free survival (LFS). Among recipients of HLA-identical sibling grafts, but not URD grafts, LFS was better in patients receiving i.v. Bu (RR, .53; P = .025) or oral Bu (RR, .64; P = .017) compared with TBI. In CML in first chronic phase, Cy in combination with i.v. Bu was associated with less relapse than TBI or oral Bu. LFS was better after i.v. or oral Bu compared with TBI. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission.
- Author
-
Warlick, Erica D., Paulson, Kristjan, Brazauskas, Ruta, Zhong, Xiaobo, Miller, Alan M., Camitta, Bruce M., George, Biju, Savani, Bipin N., Ustun, Celalettin, Marks, David I., Waller, Edmund K., Baron, Frédéric, Freytes, César O., Socie, Gérard, Akpek, Gorgun, Schouten, Harry C., Lazarus, Hillard M., Horwitz, Edwin M., Koreth, John, and Cahn, Jean-Yves
- Subjects
- *
ACUTE myeloid leukemia treatment , *CELL transplantation , *DISEASE remission , *BONE marrow transplantation , *CYTARABINE , *CORD blood , *CONFIDENCE intervals - Abstract
Abstract: The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36% (95% confidence interval [CI], 29% to 43%) in the no consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P = .16). Disease-free survival was 34% (95% CI, 27% to 41%) and 41% (95% CI, 35% to 46%; P = .15), respectively. Three-year cumulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% CI, 33% to 43%), respectively (P = .80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
14. Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research.
- Author
-
Gupta, Vikas, Malone, Adriana K., Hari, Parameswaran N., Ahn, Kwang Woo, Hu, Zhen-Huan, Gale, Robert Peter, Ballen, Karen K., Hamadani, Mehdi, Olavarria, Eduardo, Gerds, Aaron T., Waller, Edmund K., Costa, Luciano J., Antin, Joseph H., Kamble, Rammurti T., van Besien, Koen M., Savani, Bipin N., Schouten, Harry C., Szer, Jeffrey, Cahn, Jean-Yves, and de Lima, Marcos J.
- Subjects
- *
MYELOFIBROSIS , *HEMATOPOIETIC stem cell transplantation , *HLA histocompatibility antigens , *COHORT analysis , *HEALTH outcome assessment , *MEDICAL statistics , *PROGNOSIS - Abstract
Abstract: We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis (MF) using reduced-intensity conditioning (RIC). The median age at RIC HCT was 55 yr. Donors were a matched sibling donor (MSD) in 34% of RIC HCTs, an HLA well-matched unrelated donor (URD) in 45%, and a partially matched/mismatched URD in 21%. Risk stratification according to the Dynamic International Prognostic Scoring System (DIPSS) was 12% low, 49% intermediate-1, 37% intermediate-2, and 1% high. The probability of survival at 5 yr was 47% (95% confidence interval [CI], 40% to 53%). In a multivariate analysis, donor type was the sole independent factor associated with survival. Adjusted probabilities of survival at 5-yr were 56% (95% CI, 44% to 67%) for MSD, 48% (95% CI, 37% to 58%) for well-matched URD, and 34% (95% CI, 21% to 47%) for partially matched/mismatched URD (P = .002). The relative risk (RR) for NRM was 3.92 (P = .006) for well-matched URD and 9.37 (P < .0001) for partially matched/mismatched URD. Trends toward increased NRM (RR, 1.7; P = .07) and inferior survival (RR, 1.37; P = .10) were observed in DIPSS intermediate-2/high-risk patients compared with DIPSS low/intermediate-1 risk patients. Our data indicate that RIC HCT is a potentially curative option for patients with MF, and that donor type is the most important factor influencing survival in these patients. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
15. Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma
- Author
-
Hamadani, Mehdi, Saber, Wael, Ahn, Kwang Woo, Carreras, Jeanette, Cairo, Mitchell S., Fenske, Timothy S., Gale, Robert Peter, Gibson, John, Hale, Gregory A., Hari, Parameswaran N., Hsu, Jack W., Inwards, David J., Kamble, Rammurti T., Klein, Anderas, Maharaj, Dipnarine, Marks, David I., Rizzieri, David A., Savani, Bipin N., Schouten, Harry C., and Waller, Edmund K.
- Subjects
- *
LYMPHOMAS , *B cell lymphoma , *HEMATOPOIETIC stem cell transplantation , *CANCER prognosis , *CANCER invasiveness , *HEALTH outcome assessment , *PATIENTS - Abstract
Abstract: Patients with chemorefractory non-Hodgkin lymphomas generally have a poor prognosis. We used the observational database of the Center for International Blood and Marrow Transplant Research to study the outcome of 533 patients with refractory diffuse large B cell lymphoma (DLBCL) or grade III follicular lymphoma (FL-III) who underwent allogeneic hematopoietic cell transplantation (allo-HCT) using either myeloablative (MA; n = 307) or reduced-intensity/nonmyeloablative conditioning (RIC/NST; n = 226) between 1998 and 2010. We analyzed nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Only 45% of the patients at transplantation had a Karnofsky performance score of ≥90%. Median follow-up of surviving patients after MA and RIC/NST allo-HCT is 35 months and 30 months, respectively. At 3 years, MA allo-HCT was associated with a higher NRM compared with RIC/NST (53% versus 42%; P = .03), similar PFS (19% versus 23%; P = .40), and lower OS (19% versus 28%; P = .02), respectively. On multivariate analysis, FL-III histology was associated with lower NRM (relative risk [RR], .52), reduced risk of relapse/progression (RR, .42), and superior PFS (RR, .51) and OS (RR, .53), whereas MA conditioning was associated with reduced risk of relapse/progression (RR, .66). Despite a refractory state, a small subset of DLBCL and FL-III patients can attain durable remissions after allo-HCT. Conditioning regimen intensity was not associated with PFS and OS despite a higher risk of relapse/progression with RIC/NST allo-HCT. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
16. Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
- Author
-
Hamadani, Mehdi, Saber, Wael, Ahn, Kwang Woo, Carreras, Jeanette, Cairo, Mitchell S., Fenske, Timothy S., Gale, Robert Peter, Gibson, John, Hale, Gregory A., Hari, Parameswaran N., Hsu, Jack W., Inwards, David J., Kamble, Rammurti T., Klein, Anderas, Maharaj, Dipnarine, Marks, David I., Rizzieri, David A., Savani, Bipin N., Schouten, Harry C., and Waller, Edmund K.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HOMOGRAFTS , *LYMPHOMAS , *COHORT analysis , *BONE marrow transplantation , *CANCER chemotherapy , *HEALTH outcome assessment , *DISEASE progression - Abstract
Abstract: Patients with chemorefractory mantle cell lymphoma (MCL) have a poor prognosis. We used the Center for International Blood and Marrow Transplant Research database to study the outcome of 202 patients with refractory MCL who underwent allogeneic hematopoietic cell transplantation (allo-HCT) using either myeloablative (MA) or reduced-intensity/nonmyeloablative conditioning (RIC/NST), during 1998-2010. We analyzed nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS). Seventy-four patients (median age, 54 years) received MA, and 128 patients (median age, 59 years) received RIC/NST. Median follow-up after allo-HCT was 35 months in the MA group and 43 months in the RIC/NST group. At 3 years post-transplantation, no significant between-group differences were seen in terms of NRM (47% in MA versus 43% in RIC/NST; P = .68), relapse/progression (33% versus 32%; P = .89), PFS (20% versus 25%; P = .53), or OS (25% versus 30%; P = .45). Multivariate analysis also revealed no significant between-group differences in NRM, relapse, PFS, or OS; however, receipt of a bone marrow or T cell–depleted allograft was associated with an increased risk of NRM and inferior PFS and OS. Our data suggest that despite a refractory disease state, approximately 25% of patients with MCL can attain durable remission after allo-HCT, and conditioning regimen intensity does not influence outcome of allo-HCT. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
17. Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia
- Author
-
Ballen, Karen K., Woolfrey, Ann E., Zhu, Xiaochun, Ahn, Kwang Woo, Wirk, Baldeep, Arora, Mukta, George, Biju, Savani, Bipin N., Bolwell, Brian, Porter, David L., Copelan, Ed, Hale, Gregory, Schouten, Harry C., Lewis, Ian, Cahn, Jean Yves, Halter, Joerg, Cortes, Jorge, Kalaycio, Matt E., Antin, Joseph, and Aljurf, Mahmoud D.
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *POLYCYTHEMIA vera , *THROMBOCYTOSIS , *NEUTROPHILS , *DISEASE incidence - Abstract
Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure
- Author
-
Freytes, César O., Zhang, Mei-Jie, Carreras, Jeanette, Burns, Linda J., Gale, Robert Peter, Isola, Luis, Perales, Miguel-Angel, Seftel, Matthew, Vose, Julie M., Miller, Alan M., Gibson, John, Gross, Thomas G., Rowlings, Philip A., Inwards, David J., Pavlovsky, Santiago, Martino, Rodrigo, Marks, David I., Hale, Gregory A., Smith, Sonali M., and Schouten, Harry C.
- Subjects
- *
LYMPHOMAS , *STEM cell transplantation , *MORTALITY , *CANCER relapse , *FOLLOW-up studies (Medicine) , *HEALTH outcome assessment , *MEDICAL statistics - Abstract
We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21% (95% CI, 16%-27%) and 32% (95% CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study
- Author
-
Armand, Philippe, Kim, Haesook T., Zhang, Mei-Jie, Perez, Waleska S., Dal Cin, Paola S., Klumpp, Thomas R., Waller, Edmund K., Litzow, Mark R., Liesveld, Jane L., Lazarus, Hillard M., Artz, Andrew S., Gupta, Vikas, Savani, Bipin N., McCarthy, Philip L., Cahn, Jean-Yves, Schouten, Harry C., Finke, Jürgen, Ball, Edward D., Aljurf, Mahmoud D., and Cutler, Corey S.
- Subjects
- *
CYTOGENETICS , *MYELOID leukemia , *CANCER patients , *HOMOGRAFTS , *STEM cell transplantation , *KARYOTYPES , *ACUTE myeloid leukemia - Abstract
Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
20. Pregnancy after Hematopoietic Cell Transplantation: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Author
-
Loren, Alison W., Chow, Eric, Jacobsohn, David A., Gilleece, Maria, Halter, Joerg, Joshi, Sarita, Wang, Zhiwei, Sobocinski, Kathleen A., Gupta, Vikas, Hale, Gregory A., Marks, David I., Stadtmauer, Edward A., Apperley, Jane, Cahn, Jean-Yves, Schouten, Harry C., Lazarus, Hillard M., Savani, Bipin N., McCarthy, Philip L., Jakubowski, Ann A., and Kamani, Naynesh R.
- Subjects
- *
PREGNANCY , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *HUMAN fertility , *PRESERVATION of organs, tissues, etc. , *HEMATOLOGY , *APLASTIC anemia - Abstract
Preservation of fertility after hematopoietic cell transplantation (HCT) can have a significant influence on the quality of life of transplant survivors. We describe 178 pregnancies in HCT recipients that were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2002 and 2007. There were 83 pregnancies in female HCT recipients and 95 pregnancies in female partners of male HCT recipients. Indications for transplantation included hematologic and other malignancies (N = 99) and nonmalignant disorders (N = 79, of which 75 patients had severe aplastic anemia). The cohort included recipients of autologous HCT (20 women, 13 men), myeloablative (MA) allogeneic HCT (12 women, 50 men), and nonmyeloablative allogeneic HCT (2 women, 2 men). Age at HCT was <20 years for 50% of women and 19% of men. Conditioning regimens included total body irradiation (TBI) in 16% of women and 19% of men; doses were MA in 10% of women and in 16% of men. Live births were reported in 86% of pregnancies in partners of male transplant patients and 85% of pregnancies in female transplant patients, with most pregnancies occurring 5 to 10 years after HCT. We conclude that some HCT recipients can retain fertility, including patients who have received TBI and/or MA conditioning. Young patients undergoing HCT should be counseled both before and after HCT about potential loss of fertility, methods for preserving fertility, and planning for future pregnancy. Fertility and outcomes of pregnancy after HCT need prospective evaluation in large transplant cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
21. Outcome of Transplantation for Myelofibrosis
- Author
-
Ballen, Karen K., Shrestha, Smriti, Sobocinski, Kathleen A., Zhang, Mei-Jie, Bashey, Asad, Bolwell, Brian J., Cervantes, Francisco, Devine, Steven M., Gale, Robert Peter, Gupta, Vikas, Hahn, Theresa E., Hogan, William J., Kröger, Nicolaus, Litzow, Mark R., Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Schiller, Gary, Schouten, Harry C., and Roy, Vivek
- Subjects
- *
MYELOFIBROSIS , *STEM cell transplantation , *HEMATOPOIETIC stem cells , *HOMOGRAFTS , *HLA histocompatibility antigens , *GRAFT versus host disease , *THERAPEUTICS - Abstract
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
22. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
- Author
-
Lazarus, Hillard M., Zhang, Mei-Jie, Carreras, Jeanette, Hayes-Lattin, Brandon M., Ataergin, Asli Selmin, Bitran, Jacob D., Bolwell, Brian J., Freytes, César O., Gale, Robert Peter, Goldstein, Steven C., Hale, Gregory A., Inwards, David J., Klumpp, Thomas R., Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Pavlovsky, Santiago, Rizzo, J. Douglas, Shea, Thomas C., and Schouten, Harry C.
- Subjects
- *
HODGKIN'S disease , *BONE marrow transplant complications , *COHORT analysis , *AUTOTRANSPLANTATION , *HEALTH outcome assessment , *MORTALITY - Abstract
We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged ≥18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P < .001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P < .001), and mortality (RR 2.75, 95% CI, 2.03-3.72, P < .001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
23. The Effect of Smoking on Allogeneic Transplant Outcomes
- Author
-
Marks, David I., Ballen, Karen, Logan, Brent R., Wang, Zhiwei, Sobocinski, Kathleen A., Bacigalupo, Andrea, Burns, Linda J., Gupta, Vikas, Ho, Vincent, McCarthy, Philip L., Ringdén, Olle, Schouten, Harry C., Seftel, Matthew, and Rizzo, J. Douglas
- Subjects
- *
HOMOGRAFTS , *PHYSIOLOGICAL effects of tobacco , *HEALTH outcome assessment , *CHRONIC myeloid leukemia , *MULTIVARIATE analysis , *ORGAN donors , *QUALITY of life , *SURVIVAL analysis (Biometry) , *LONGITUDINAL method - Abstract
Using the Center for Internaitonal Blood and Marrow Transplant Research (CIBMTR) data, we compared the transplant outcomes of patients with chronic myelogenous leukemia (CML) who were nonsmokers (NS) and past or current smokers (PCS). There were 2193 NS and 625 PCS who received matched sibling and unrelated donor allografts for CML in first chronic phase. We looked for dose effects and identified low and high dose smoking groups (>10 pack years, >1 pack per day). Outcomes were adjusted for known prognostic variables including the European Group for Blood and Marrow Transplant (EBMT) risk score. In multivariate analyses of sibling allograft recipients, relapse risk (RR) was higher (RR=1.67, P =.003) in smokers than NS, but the dose effects were not consistent. High-dose smokers experienced a 50% treatment-related mortality (TRM) versus 28% in the NS group at 5 years on univariate analysis, and the RR was 1.57 (P =.005) on multivariate analysis. Overall survival (OS) at 5 years was 68% in NS versus 62% in the low-dose smoking group versus 50% in the high-dose smoking group (P < .001). Smoking did not significantly affect outcomes in unrelated donor recipients, but numbers were smaller. High-dose smoking is associated with a reduction in OS in patients having sibling allografts for CML. A prospective study with detailed demographic, pulmonary function, and quality-of-life data would improve our understanding of this issue. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
24. Quality of Life and Non-Pain Symptoms in Patients with Cancer
- Author
-
van den Beuken-van Everdingen, Marieke H.J., de Rijke, Janneke M., Kessels, Alfons G., Schouten, Harry C., van Kleef, Maarten, and Patijn, Jacob
- Subjects
- *
CANCER patient medical care , *QUALITY of life , *CANCER pain , *PAIN management , *PALLIATIVE treatment , *ANTINEOPLASTIC agents - Abstract
Abstract: To measure the prevalence of non-pain physical symptoms and psychological symptoms in patients with cancer, to investigate the impact of physical and psychological symptoms on their quality of life (QoL), and to inquire whether treatment had been received for the complaints/symptoms, a representative sample of 1,429 cancer patients were recruited and classified according to tumor type and treatment status [i.e., (1a) curative treatment >6 months ago, (1b) curative treatment ≤6 months ago, (2) palliative antitumor treatment, and (3) treatment no longer feasible]. QoL and non-pain symptoms were measured by the European Organisation for Research and Treatment of Cancer (EORTC)-C30 version 3. We added two items: (1) Did you have a dry mouth? and (2) Did you feel listless? We also asked whether the patients had received treatment for their symptoms. Depression and anxiety were measured by the Dutch version of the Hospital Anxiety and Depression Scale. One-way analysis of variance (ANOVA) was used to detect differences in global QoL between patients with different types of cancer. When ANOVA was significant, post hoc tests (Tukey) were performed to identify significant differences among cancer types. Linear regression analyses (forced entrance procedure) were performed to investigate the influence of physical and psychological symptoms on global QoL. The prevalence of moderate-to-severe symptoms increased significantly with each disease group. Vomiting and irritability were the least prevalent symptoms, and fatigue and worries were the most prevalent symptoms in all groups. Patients in Group 1 (curative treatment) experienced symptoms that were independent of cancer type. Patients in Group 2 (palliative treatment) experienced symptoms that varied with cancer type. QoL decreased significantly each step from Group 1 through 3. Fatigue, appetite loss, constipation, dry mouth, depression, and anxiety had independent negative influences on QoL. Patients with gastrointestinal cancer, malignant lymphoma, and other hematological malignancies had significantly poorer QoL than patients with prostate cancer. In 45%–90% of patients, symptoms remained untreated. Non-pain physical symptoms and psychological symptoms are frequent in patients with cancer at all disease phases. Many symptoms remain untreated. Systematic recording of symptom intensity should be mandatory, irrespective of the phase of disease. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
25. Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)
- Author
-
Lazarus, Hillard M., Carreras, Jeanette, Boudreau, Christian, Loberiza, Fausto R., Armitage, James O., Bolwell, Brian J., Freytes, César O., Gale, Robert Peter, Gibson, John, Hale, Gregory A., Inwards, David J., LeMaistre, Charles F., Maharaj, Dipnarine, Marks, David I., Miller, Alan M., Pavlovsky, Santiago, Schouten, Harry C., van Besien, Koen, Vose, Julie M., and Bitran, Jacob D.
- Subjects
- *
HODGKIN'S disease , *CELL transplantation , *HEMATOPOIETIC stem cells , *BONE marrow transplantation , *HEALTH outcome assessment , *MULTIVARIATE analysis , *MEDICAL care research , *PATIENTS - Abstract
Abstract: To compare the clinical outcomes of older (age ≥55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL patients (<55 years) receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in 805 NHL patients aged ≥55 years to 1949 NHL patients <55 years during the years 1990–2000 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). In multivariate analysis, older patients with aggressive histologies were 1.86 times (95% confidence interval [CI] 1.43-2.43, P < .001) more likely than younger patients to experience treatment-related mortality (TRM). Relative death risks were 1.33 times (CI 1.04-1.71, P = .024) and 1.50 times (CI 1.33-16.9, P < .001) higher in older compared to younger patients with follicular grade I/II and aggressive histologies, respectively. Autologous HCT in older NHL patients is feasible, but most disease-related outcomes are statistically inferior to younger patients. Studies addressing supportive care particular to older patients, who are most likely to benefit from this approach, are recommended. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
26. Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant
- Author
-
Smith, Sonali M., van Besien, Koen, Carreras, Jeanette, Bashey, Asad, Cairo, Mitchell S., Freytes, Cesar O., Gale, Robert Peter, Hale, Gregory A., Hayes-Lattin, Brandon, Holmberg, Leona A., Keating, Armand, Maziarz, Richard T., McCarthy, Philip L., Navarro, Willis H., Pavlovsky, Santiago, Schouten, Harry C., Seftel, Matthew, Wiernik, Peter H., Vose, Julie M., and Lazarus, Hillard M.
- Subjects
- *
LYMPHOMAS , *RETICULOENDOTHELIAL granulomas , *LYMPHOPROLIFERATIVE disorders , *ADENOLYMPHOMA - Abstract
Abstract: We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes for patients with either Hodgkin lymphoma (HL, n = 21) or non-Hodgkin lymphoma (NHL, n = 19) receiving HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were analyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58%) patients had a Karnofsky performance score <90. HCT2 was performed >1 year after HCT1 in 82%. The probability of treatment-related mortality at day 100 was 11% (95% confidence interval [CI], 3%-22%). The 1-, 3-, and 5-year probabilities of PFS were 50% (95% CI, 34%-66%), 36% (95% CI, 21%-52%), and 30% (95% CI, 16%-46%), respectively. Corresponding probabilities of survival were 65% (95% CI, 50%-79%), 36% (95% CI, 22%-52%), and 30% (95% CI, 17%-46%), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients (73%) have died, 18 (62%) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
27. Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning
- Author
-
Hari, Parameswaran, Carreras, Jeanette, Zhang, Mei-Jie, Gale, Robert Peter, Bolwell, Brian J., Bredeson, Christopher N., Burns, Linda J., Cairo, Mitchell S., Freytes, César O., Goldstein, Steven C., Hale, Gregory A., Inwards, David J., LeMaistre, Charles F., Maharaj, Dipnarine, Marks, David I., Schouten, Harry C., Slavin, Shimon, Vose, Julie M., Lazarus, Hillard M., and van Besien, Koen
- Subjects
- *
STEM cells , *CELLULAR therapy , *DRUG therapy , *BLOOD cells - Abstract
Abstract: Reduced-intensity conditioning (RIC) regimens have been increasingly used for allogeneic hematopoietic stem cell transplantation (HSCT) in follicular lymphoma (FL). We compared traditional myeloablative conditioning regimens to RIC in FL. Outcomes of HLA-identical sibling HSCT for FL in 208 recipients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1997 and 2002 were studied. Conditioning regimens were categorized as myeloablative (N = 120) or RIC (N = 88). Use of RIC regimens increased from <10% of transplants in 1997 to >80% in 2002 signaling a major shift in practice. Patients receiving RIC were older and had a longer interval from diagnosis to transplant. These differences did not correlate with outcomes. Median follow-up of survivors was 50 months (4-96 months) after myeloablative conditioning versus 35 months (4-82 months) after RIC (P < .001). At 3 years, overall survival (OS) for the myeloablative and RIC cohorts were 71 (63%-79%) and 62 (51%-72%; P = .15) and progression free survival (PFS), 67 (58%-75%) and 55 (44%-65%; P = .07), respectively. Lower Karnofsky performance score (KPS) and resistance to chemotherapy were associated with higher treatment-related mortality (TRM) and lower OS and PFS. On multivariate analysis, an increased risk of lymphoma progression after RIC was observed (relative risk = 2.97, P = .04). RIC has become the de facto standard in allogeneic HSCT for FL, and appears to result in similar long-term outcomes. Although disease-free survival (DPS) is similar compared to myeloablative conditioning, an increased risk of late disease progression after RIC is concerning. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
28. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:: A randomised phase II trial from HOVON, the Dutch–Belgian Haemato-Oncology Working Group for adults
- Author
-
Daenen, Simon, van der Holt, Bronno, Verhoef, Gregor E.G., Löwenberg, Bob, Wijermans, Pierre W., Huijgens, Peter C., van Marwijk Kooy, Rien, Schouten, Harry C., Kramer, Mark H.H., Ferrant, Augustin, van den Berg, Eva, Steijaert, Monique M.C., Verdonck, Leo F., and Sonneveld, Pieter
- Subjects
- *
CYCLOSPORINE , *ACUTE myeloid leukemia , *IMMUNOSUPPRESSIVE agents , *MYELOID leukemia - Abstract
Cyclosporin A (CsA) inhibits the P-gp pump that can be responsible for failure of cytostatic treatment in acute myeloid leukaemia (AML). Eighty patients with relapsing/refractory AML were randomly assigned to mitoxantrone (M) and etoposide (VP) (MVP) in unmitigated antileukaemic doses with or without CsA, to investigate if toxicity was manageable and if antileukaemic therapy could be improved. CsA did not delay haematological recovery, but fewer CsA patients received post-induction therapy because of haematological and non-haematological toxicity. CR rate was 43% for MVP and 53% for CsA; DFS was 9 and 8 months, and OS 8 and 9 months, respectively. Seventeen of 38 CR patients proceeded to stem cell transplantation (SCT). After a median follow-up of 66 months, six patients were still alive. Addition of CsA did not improve treatment outcome, possibly due to inadequate post-induction therapy as a result of increased toxicity. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
29. A randomized multicenter comparison of CD34+-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies
- Author
-
Cornelissen, Jan J., van der Holt, Bronno, Petersen, Eefke J., Vindelov, Lars, Russel, Charlotte A., Höglund, Martin, Maertens, Johan, Schouten, Harry C., Braakman, Eric, Steijaert, Monique M.C., Zijlmans, Mark J.M., Slaper-Cortenbach, Ineke, Boogaerts, Marc A., Löwenberg, Bob, and Verdonck, Leo F.
- Subjects
- *
BLOOD cells , *HEMATOPOIETIC stem cells , *HOMOGRAFTS , *GRAFT versus host disease - Abstract
Objective. Peripheral blood progenitor cells (PBPC) have been established as an alternative source of hematopoietic stem cells for allogeneic transplantation, but an increased incidence of both acute and chronic graft-vs-host disease (GVHD) has become apparent. We performed a prospective randomized trial comparing bone marrow transplantation (BMT) vs PBPC transplantation (PBPCT) using CD34+ selection for T-cell depletion (TCD) in both study arms.Patients and Methods. Between January 1996 and October 2000, 120 patients with a diagnosis of acute leukemia, myelodysplasia, multiple myeloma, or lymphoma were randomized to receive either filgrastim-mobilized PBPC or BM from HLA-identical sibling donors after standard high-dose chemoradiotherapy. Patient characteristics did not differ between study arms.Results. Recipients of PBPC received more CD3+ T cells (median: 3.0 vs 2.0×105/kg, p<0.0001) and more CD34+ cells (median: 3.6 vs 0.9×106/kg, p<0.0001). Neutrophil and platelet recoveries occurred significantly faster after PBPCT. The cumulative incidence of acute GVHD grades II–IV was 37% after BMT vs 52% after PBPCT and was most significantly (p = 0.007) affected by the number of CD3+ T cells in the graft. Acute GVHD appeared strongly associated with increased treatment-related mortality (TRM) in a time-dependent analysis. Higher numbers of CD34+ cells were associated with less TRM. With a median follow-up of 37 months (range: 12–75), overall survival at 4 years from transplantation was 60% after BMT and 34% for recipients of PBPCT (p = 0.04), which difference was largely due to increased GVHD and TRM in PBPC recipients receiving T-cell dosages greater than 2×105/kg.Conclusion. Outcome following T cell–depleted PBPCT critically depends on the number of CD3+ T cells, whereby high T-cell numbers may blunt a favorable effect of higher CD34+ cell numbers. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
30. 503 - Impact of Donor Type in Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Conditioning: A Study From the Alwp of the Ebmt and Eurocord.
- Author
-
Baron, Frédéric, Labopin, Myriam, Ruggeri, Annalisa, Cornelissen, Jan, Meijer, Ellen, Sengeloev, Henrik, Niederwieser, Dietger, de Groot, Marco R., Schouten, Harry C., Milpied, Noel, Blaise, Didier, Savani, Bipin N., Gluckman, Eliane, Mohty, Mohamad, and Nagler, Arnon
- Published
- 2018
- Full Text
- View/download PDF
31. 276 - Autologous Vs Related Vs Unrelated Hematopoietic Stem Cell Transplantation for Adults with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the EBMT.
- Author
-
Poiré, Xavier, Labopin, Myriam, Blaise, Didier, Chevallier, Patrice, Maertens, Johan A., Deconinck, Eric, Forcade, Edouard, Rambaldi, Alessandro, Baerlocher, Gabriela M., Zuckerman, Tsila, Volin, Liisa, Schouten, Harry C., Ifrah, Norbert, Esteve, Jordi, Mohty, Mohamad, and Nagler, Arnon
- Subjects
- *
ACUTE myeloid leukemia treatment , *HEMATOPOIETIC stem cell transplantation , *AUTOGRAFTS , *GENETIC mutation , *DISEASE remission - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.